Would you discontinue dabrafenib/trametinib in a patient with BRAF mutant metastatic lung cancer if you see mild cardiomyopathy which could be related to the drugs?   

Patient does not want chemo but is tolerating these well otherwise. 



Answer from: Medical Oncologist at Community Practice